Results for &quot;&quot;Genes, erbB-1&quot;&quot;[mesh_terms]

Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas.

Michael Meister, Peter Schirmacher, Hendrik Dienemann, Gunhild Mechtersheimer, Philipp A Schnabel, Michael A Kern, Esther Herpel, Elizabeth C Xu, Thomas Muley, Michael Thomas, Ralf J Rieker

Cancer letters 2007;248(2):186-91

Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy.

D M Kweekel, H Gelderblom, H-J Guchelaar

Cancer treatment reviews 2005;31(2):90-105

Brain natriuretic peptide modulates calcium homeostasis and epidermal growth factor receptor gene signalling in asthmatic airways smooth muscle cells.

Augusto Orlandi, Luigino Calzetta, Elena Doldo, Chiara Tarquini, Maria Gabriella Matera, Daniela Passeri

Pulmonary pharmacology & therapeutics 2016;31():51-4

Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.

Thomas Zander, Matthias Scheffler, Lucia Nogova, Carsten Kobe, Walburga Engel-Riedel, Martin Hellmich, Irini Papachristou, Karin Toepelt, Andreas Draube, Lukas Heukamp, Reinhard Buettner, Yon D Ko, Roland T Ullrich, Egbert Smit, Ronald Boellaard, Adriaan A Lammertsma, Michael Hallek, Andreas H Jacobs, Andreas Schlesinger, Karin Schulte, Silvia Querings, Erich Stoelben, Bernd Neumaier, Roman K Thomas, Markus Dietlein, Jürgen Wolf

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(13):1701-8

Metabolic Phenotypes, Dependencies, and Adaptation in Lung Cancer.

Gina M DeNicola, David B Shackelford

Cold Spring Harbor perspectives in medicine 2021;11(11):a037838

Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.

Matthias Scheffler, Thomas Zander, Lucia Nogova, Carsten Kobe, Deniz Kahraman, Markus Dietlein, Irini Papachristou, Lukas Heukamp, Reinhard Büttner, Ron Boellaard, Adriaan A Lammertsma, Silvia Querings, Erich Stoelben, Walburga Engel-Riedel, Bernd Neumaier, Jürgen Wolf

PloS one 2013;8(1):e53081

Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.

Dongsheng Yue, Shidong Xu, Qun Wang, Xiaofei Li, Yi Shen, Heng Zhao, Chun Chen, Weimin Mao, Wei Liu, Junfeng Liu, Lanjun Zhang, Haitao Ma, Qiang Li, Yue Yang, Yongyu Liu, Haiquan Chen, Changli Wang

The Lancet. Respiratory medicine 2019;6(11):863-873

The use of EGFR exon 19 and 21 unlabeled DNA probes to screen for activating mutations in non-small cell lung cancer.

Carlynn Willmore-Payne, Joseph A Holden, Carl T Wittwer, Lester J Layfield

Journal of biomolecular techniques : JBT 2009;19(3):217-24

siGCD: a web server to explore survival interaction of genes, cells and drugs in human cancers.

XiuLiang Cui, Lu Han, Yang Liu, Ying Li, Wen Sun, Bin Song, Wenxia Zhou, Yongxiang Zhang, Hongyang Wang

Briefings in bioinformatics 2021;22(5):bbab058

Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer.

Hongyan Ying, Xian-Da Yang, Zhao Sun, Xiaohong Ning, Yingyi Wang, Chunmai Bai, Shuchang Chen, Yuzhou Wang

Medical oncology (Northwood, London, England) 2015;31(10):220

Long-term survival with glioblastoma multiforme.

Dietmar Krex, Barbara Klink, Christian Hartmann, Andreas von Deimling, Torsten Pietsch, Matthias Simon, Michael Sabel, Joachim P Steinbach, Oliver Heese, Guido Reifenberger, Michael Weller, Gabriele Schackert

Brain : a journal of neurology 2007;130(Pt 10):2596-606

Predictors of response to systemic therapy in breast cancer.

Alistair E Ring, Paul A Ellis

Forum (Genoa, Italy) 2003;12(1):19-32

Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis.

G D Smith, B E Chadwick, C Willmore-Payne, J S Bentz

Journal of clinical pathology 2008;61(4):487-93

Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer.

Masafumi Takeshita, Takaomi Koga, Koichi Takayama, Tokujiro Yano, Yoshihiko Maehara, Yoichi Nakanishi, Katsuo Sueishi

Cancer biology & therapy 2011;10(9):933-41